- |||||||||| prednisolone / Generic mfg.
Journal: Diagnosis and treatment of non-infectious uveitis associated with systemic disease: a guide for internists (Pubmed Central) - Nov 6, 2020
Anterior uveitis is the only form that responds to topical therapies (prednisolone acetate and mydriatics). The other forms of inflammatory and non-infectious uveitis often require treatment with systemic corticosteroids, followed by immunosuppressive or biological therapies, which requires close collaboration between the different medical sub-specialties.
- |||||||||| prednisolone / Generic mfg.
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: PRedSS: Prednisolone in Early Diffuse Systemic Sclerosis (clinicaltrials.gov) - Nov 6, 2020
P2, N=72, Recruiting,
The other forms of inflammatory and non-infectious uveitis often require treatment with systemic corticosteroids, followed by immunosuppressive or biological therapies, which requires close collaboration between the different medical sub-specialties. Active, not recruiting --> Recruiting | N=25 --> 72 | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||||||||| cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] The Clinical Features of Multiple Myeloma with AL Amyloidosis () - Nov 5, 2020 - Abstract #ASH2020ASH_5283;
Conclusion Multiple myeloma with AL amyloidosis, especially cardiac or hepatic amyloidosis, has a poor prognosis even if treated with novel agents. Searching for the optimal treatment for these patient groups remains to be an issue.
- |||||||||| Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3rd Interim Analysis of the German Non-Interventional Trial RISA () - Nov 5, 2020 - Abstract #ASH2020ASH_4839;
Mean±SD age was 63.1±17.4 years, median (range) duration of ITP was 5.6 (0.0- 44.9) years, 10% were splenectomized, 52.4% were female, median platelet count (range) at baseline was 33.5x109/L (0.0-270.0), 37.6% reported bleeding complications (any grade) within 12 months prior baseline (WHO °I 30% , °II 4.8% , °III 1.9% , °IV 0% , 1% grade missing), 85.2% received prior ITP therapy, and 81.4% had at least one concomitant disease. At least one pre-treatment was given to 179 patients.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3833;
P3
Introduction: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone) remains the standard of care for first-line (1L) treatment of diffuse large B-cell lymphoma (DLBCL), with a long-term event free survival of 60–70% in patients (pts) who complete the recommended treatment course of 6–8 cycles (Coiffier, et al...Methods : We performed an exploratory analysis based on 1,407 newly diagnosed DLBCL pts from the Phase III GOYA trial [NCT01287741] who were treated with R-CHOP or obinutuzumab in combination with CHOP (G-CHOP)...Conclusions : Future analyses will evaluate TRAIL on the hold-out test set to estimate a final unbiased measure of performance as well as an evaluation in an independent clinical trial. This model has the potential to be used as clinical decision support to guide physician judgement and enable patient enrollment into future clinical trials for alternate therapies, as well as alleviate anti-CD20 or R-CHOP associated toxicities for 1L DLBCL patients who are unlikely to derive the full benefit of this treatment.
- |||||||||| Darzalex IV (daratumumab) / J&J
[VIRTUAL] Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2846;
Proteasome inhibitors (PI), such as bortezomib, carfilzomib, and ixazomib used for multiple myeloma treatment are also used for the treatment of AL amyloidosis...Results : Cyclophosphamide, Bortezomib, Dexamethasone (CyBorD) with or without Daratumumab (Dara): In a Phase lll trial (ANDEROMADA study), Palldini et al...Bortezomib, Melphalan, Prednisolone (BMP): In a retrospective study by Lee et al...Further prospective clinical trials are warranted for a broader understanding of the safety and efficacy profile of PI-based regimens and correlation with individual pts characteristics. Table Caption: Table 1: Comparative efficacy and safety of proteasome-inhibitor based drug regimens in ND-AL
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2584;
Here, we present an interim analysis of ctDNA kinetics from ACCEPT, a phase Ib/II study of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with previously untreated DLBCL...One patient from the first acalabrutinib dose escalation cohort and the second patient was found to be ineligible and withdrawn from the primary analysis because of continuous co-administration of omeprazole during therapy which inhibits acalabrutinib absorption...The rapid kinetics of the changes in ctDNA is noted and is potentially of advantage over other modalities of monitoring, such as PET-CT scan. Data on the entire cohort (n=30) and longer follow-up will be available at the time of the meeting.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial (Channel 19 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1609;
Children with M1 (< 5% blasts) or M2 (< 25% and ≥ 5% blasts) marrow were randomized 1:1 after induction therapy and cycles of HC1 and HC2 chemotherapy, administered according to the IntReALL HR 2010, ALL-REZ BFM 2002, ALL R3, COOPRALL, and AIEOP ALL REC 2003 protocols, to receive a third consolidation course with blinatumomab (15 µg/m2/day for 4 weeks) or HC3 (dexamethasone, vincristine, daunorubicin, methotrexate, ifosfamide, PEG-asparaginase); intrathecal chemotherapy (methotrexate/cytarabine/prednisolone) was administered before treatment. Blinatumomab monotherapy as consolidation therapy before alloHSCT in children with HR first-relapse BCP-ALL leads to significantly better EFS, lower risk of recurrence, and fewer grade ≥ 3 treatment-emergent AEs vs HC3, suggesting a new standard‑of-care treatment for these patients.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Predictors of Glucocorticoid Responsiveness in Multicentric Castleman’s Disease (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1458;
Furthermore, PSL doses could be tapered to safer doses among patients who could continue PSL until the latest follow-up. In contrast, the efficacy of glucocorticoids for MCD patients with lower Hb or higher CRP levels were limited.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_981;
Among patients in the FH database who received R-CHOP as first LoT and had available dosing data, those who received <80% of standard full doses for cyclophosphamide (750mg/m2) and doxorubicin (50mg/m2) at first administration were classified as “reduced-dose” R-CHOP...More than half of the treated patients received R-CHOP in the first LoT (63% and 53% in FH and SEER-M, respectively); other patients received attenuated regimens, including rituximab plus bendamustine (R-Benda), rituximab plus cyclophosphamide, vincristine and prednisolone (R-CVP), and rituximab (R) monotherapy...These data show a high unmet medical need among elderly patients with DLBCL who may not be able to tolerate immunochemotherapy regimens that have been evaluated in trials for a carefully selected patient population. Further research will aim to assess prognostic factors at the time of treatment initiation, as well as gather information on comorbidities and other factors that may prevent elderly patients from receiving SoC R-CHOP; these patients may be candidates for better-tolerated novel approaches.
- |||||||||| prednisolone / Generic mfg., arsenic trioxide / Generic mfg.
[VIRTUAL] Disseminated Intravascular Coagulation Score Evolution in 48 Hours Predicts Early Death in Newly-Diagnosed Chemotherapy-Treated Acute Promyelocytic Leukemia Patients (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_763;
Methods This retrospective, single-center study, included consecutively admitted patients with newly diagnosed genetically confirmed Acute Promyelocytic Leukemia between 2000 and 2020, who were treated with ATRA + anthracycline protocols and prednisolone 0.5 mg/kg differentiation syndrome prophylaxis...Results A total of 67 patients were included, after excluding 9 patients for missing coagulation values, 8 for first-line arsenic trioxide treatment, and 7 patients for death within 48 hours of hospital admission...These findings identified a new independent predictor of early death using a dynamic DIC Score assessment, which is easily accessible and calculated, and illustrate how this score can be applied daily in the clinical care of APL patients. Together with the current APL treatment strategies, the intensification of measures to control the leukemia-associated coagulopathy in patients who do not show a DIC Score improvement in the first 48 hours after diagnosis could decrease the early death rate in this otherwise highly-curable leukemia.
- |||||||||| prednisolone / Generic mfg., triptorelin / Generic mfg.
[VIRTUAL] Diagnosis and treatment of precocious puberty in the Mexican population: a case report () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_712;
In natural history, the CPP conditions a shorter size than the expected, a decreased in bone mineral density, conditioning a higher risk of osteoporosis, a precocious development of secondary sexual characters, an menarche at less age than habitual, with the consequent early ovary fail, predisposing CV an cancer, coupled with psychosocial problems.The essential points for the diagnostic are the clinical data that they present, mainly oriented on the tanner scale. In Mexican population, we don’t count with a specific scale to classify the sexual character development.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion date, FDG PET, Metastases: RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - Nov 4, 2020
P3, N=1202, Active, not recruiting,
In Mexican population, we don’t count with a specific scale to classify the sexual character development. Trial completion date: Jan 2020 --> Jan 2021
- |||||||||| prednisolone / Generic mfg., entecavir / Generic mfg.
Clinical, Journal: Pyoderma gangrenosum at multiple sites in a post-colostomy ulcerative colitis patient with chronic hepatitis B virus: A case report. (Pubmed Central) - Nov 4, 2020
In the current report, we describe a case of pyoderma gangrenosum in a post-colostomy ulcerative colitis patient with chronic hepatitis B. Pyoderma gangrenosum began seemingly as peristomal dermatitis that rapidly developed into painful ulcerations with subsequent appearance of sterile pustules and ulcerations in the left lower leg. The patient significantly improved after active management with prednisolone, antiviral therapy with entecavir, and wound dressings. Our case suggests that physicians and surgeons should have a high index of suspicion of pyoderma gangrenosum in post-colostomy ulcerative colitis patients who develop peristomal dermatitis.
- |||||||||| dexamethasone / Generic mfg., prednisolone / Generic mfg.
Clinical, Journal, HEOR: Dexamethasone or prednisolone for asthma exacerbations in children: A cost-effectiveness analysis. (Pubmed Central) - Nov 3, 2020
However, combination therapy was not found to be beneficial for the treatment of spasms or developmental outcomes when compared to hormonal therapy alone. The present study shows that in Colombia, a middle-income country, compared with oral dexamethasone, the use of prednisolone for treating acute pediatric asthma is cost-effective, yielding a similar probability of hospitalization at lesser overall costs.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J
Journal: Neurosarcoidosis (Brain) (Pubmed Central) - Nov 3, 2020
Therefore, the pathologic diagnosis of brain lesions is the gold standard for diagnosing neurosarcoidosis. In addition to prednisolone therapy, infliximab, a monoclonal antibody against tumor necrosis factor-α, has received much attention for treating neurosarcoidosis.
- |||||||||| prednisolone / Generic mfg.
Journal: Is Prednisolone Useful in Treatment of Hyperemesis Gravidarum? (Pubmed Central) - Nov 3, 2020
In addition to prednisolone therapy, infliximab, a monoclonal antibody against tumor necrosis factor-α, has received much attention for treating neurosarcoidosis. Prednisolone is effective for treating women with hyperemesis gravidarum during the first trimester of pregnancy.
- |||||||||| prednisolone / Generic mfg.
Clinical, Journal: An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up. (Pubmed Central) - Nov 3, 2020
Adult patients with rheumatic diseases receiving prednisolone ≥0.6 mg/kg/day were randomized into the single-strength group (SS; SMX/TMP 400/80 mg daily), the half-strength group (HS; 200/40 mg daily) or the escalation group (ES; starting at 40/8 mg and increasing incrementally to 200/40 mg daily) and treated for 24 weeks, then observed for 52 weeks...SMX/TMP 200/40 mg had a high PCP prevention rate and was superior to SMX/TMP 400/80 mg in terms of drug retention and safety. University Hospital Medical Information Network Clinical Trials Registry, UMIN000007727.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Clinical, Journal: Omalizumab in patients with NSAIDs-exacerbated respiratory disease. (Pubmed Central) - Oct 30, 2020
OCT angiography and electroretinogram are useful techniques for monitoring the effectiveness of the treatments. Omalizumab is an effective therapy option in N-ERD patients in a 9 month study period.
- |||||||||| prednisolone / Generic mfg.
Clinical, Journal: Associated clinical factors for serious infections in patients with systemic lupus erythematosus. (Pubmed Central) - Oct 28, 2020
The conditional logistic regression analysis with adjustment showed that serositis (OR, 2.76; 95% CI, 1.33-5.74), hematologic involvement (OR, 2.53; 95% CI, 1.32-4.87), and use of higher than the low dose of glucocorticoids (GCs; >7.5 mg/d prednisolone-equivalent) (OR, 2.65; 95% CI, 1.31-5.34) were related to serious infections in SLE. Serositis, hematologic involvement, and use of higher than the low dose of GCs were associated with serious infections in patients with SLE.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Pembrolizumab-induced thrombotic thrombocytopenic purpura. (Pubmed Central) - Oct 28, 2020
This case is one of only two linking anti-PD-1 therapy to thrombotic thrombocytopenic purpura development (the other occurring in a patient on nivolumab plus ipilimumab). Thrombotic thrombocytopenic purpura is life-threatening and clinicians are advised to be aware of its possible occurrence in immune checkpoint inhibitor-treated patients.
|
